These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 9145678)

  • 1. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer.
    Krainer M; Silva-Arrieta S; FitzGerald MG; Shimada A; Ishioka C; Kanamaru R; MacDonald DJ; Unsal H; Finkelstein DM; Bowcock A; Isselbacher KJ; Haber DA
    N Engl J Med; 1997 May; 336(20):1416-21. PubMed ID: 9145678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer.
    FitzGerald MG; MacDonald DJ; Krainer M; Hoover I; O'Neil E; Unsal H; Silva-Arrieto S; Finkelstein DM; Beer-Romero P; Englert C; Sgroi DC; Smith BL; Younger JW; Garber JE; Duda RB; Mayzel KA; Isselbacher KJ; Friend SH; Haber DA
    N Engl J Med; 1996 Jan; 334(3):143-9. PubMed ID: 8531968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
    Roa BB; Boyd AA; Volcik K; Richards CS
    Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.
    Neuhausen S; Gilewski T; Norton L; Tran T; McGuire P; Swensen J; Hampel H; Borgen P; Brown K; Skolnick M; Shattuck-Eidens D; Jhanwar S; Goldgar D; Offit K
    Nat Genet; 1996 May; 13(1):126-8. PubMed ID: 8673092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%.
    Oddoux C; Struewing JP; Clayton CM; Neuhausen S; Brody LC; Kaback M; Haas B; Norton L; Borgen P; Jhanwar S; Goldgar D; Ostrer H; Offit K
    Nat Genet; 1996 Oct; 14(2):188-90. PubMed ID: 8841192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
    Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E
    Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
    Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ
    Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
    Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E
    Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 and BRCA2 founder mutations in patients with bilateral breast cancer.
    Gershoni-Baruch R; Dagan E; Fried G; Kepten I; Robinson E
    Eur J Hum Genet; 1999; 7(7):833-6. PubMed ID: 10573018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 mutations in a population-based sample of young women with breast cancer.
    Langston AA; Malone KE; Thompson JD; Daling JR; Ostrander EA
    N Engl J Med; 1996 Jan; 334(3):137-42. PubMed ID: 8531967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals.
    Berman DB; Costalas J; Schultz DC; Grana G; Daly M; Godwin AK
    Cancer Res; 1996 Aug; 56(15):3409-14. PubMed ID: 8758903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
    Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA
    N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany.
    Hamann U; Liu X; Bungardt N; Ulmer HU; Bastert G; Sinn HP
    Eur J Hum Genet; 2003 Jun; 11(6):464-7. PubMed ID: 12774040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Offit K; Foulkes W; Robson ME; Wacholder S; Eng CM; Karp SE; Begg CB
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):467-73. PubMed ID: 11352856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
    Modan B; Hartge P; Hirsh-Yechezkel G; Chetrit A; Lubin F; Beller U; Ben-Baruch G; Fishman A; Menczer J; Struewing JP; Tucker MA; Wacholder S;
    N Engl J Med; 2001 Jul; 345(4):235-40. PubMed ID: 11474660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients.
    Manguoglu AE; Lüleci G; Ozçelik T; Colak T; Schayek H; Akaydin M; Friedman E
    Hum Mutat; 2003 Apr; 21(4):444-5. PubMed ID: 12655560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient.
    Tsongalis GJ; Linfert DR; Johnson RC; Ackroyd R; Berman MM; Ricci A
    Arch Pathol Lab Med; 1998 Jun; 122(6):548-50. PubMed ID: 9625424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of BRCA1 and BRCA2 germline mutations to the incidence of early-onset breast cancer in Cyprus.
    Loizidou M; Marcou Y; Anastasiadou V; Newbold R; Hadjisavvas A; Kyriacou K
    Clin Genet; 2007 Feb; 71(2):165-70. PubMed ID: 17250666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India.
    Hedau S; Jain N; Husain SA; Mandal AK; Ray G; Shahid M; Kant R; Gupta V; Shukla NK; Deo SS; Das BC
    Breast Cancer Res Treat; 2004 Nov; 88(2):177-86. PubMed ID: 15564800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.